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Thomas Müller*Abstract
Parkinson`s disease (PD) is a progressive, disabling neurodegenerative disorder with onset of motor and non-motor
features. Both reduce quality of life of PD patients and cause caregiver burden. This review aims to provide a survey
of possible therapeutic options for treatment of motor and non motor symptoms of PD and to discuss their relation
to each other. MAO-B-Inhibitors, NMDA antagonists, dopamine agonists and levodopa with its various application
modes mainly improve the dopamine associated motor symptoms in PD. This armentarium of PD drugs only partially
influences the onset and occurrence of non motor symptoms. These PD features predominantly result from non
dopaminergic neurodegeneration. Autonomic features, such as seborrhea, hyperhidrosis, orthostatic syndrome,
salivation, bladder dysfunction, gastrointestinal disturbances, and neuropsychiatric symptoms, such as depression,
sleep disorders, psychosis, cognitive dysfunction with impaired execution and impulse control may appear. Drug
therapy of these non motor symptoms complicates long-term PD drug therapy due to possible occurrence of drug
interactions, - side effects, and altered pharmacokinetic behaviour of applied compounds. Dopamine substituting
compounds themselves may contribute to onset of these non motor symptoms. This complicates the differentiation
from the disease process itself and influences therapeutic options, which are often limited because of additional
morbidity with necessary concomitant drug therapy.
Keywords: Motor symptoms, Parkinson’s disease, non motor features, drug therapyIntroduction
Parkinson`s disease (PD) is a progressive, disabling neu-
rodegenerative disorder. This disease is characterized by
an insidious onset with variable expression of predomin-
ant motor, vegetative, sensory and psychopathological
symptoms. Ongoing loss of nigral dopaminergic pre-
synaptic neurons with a reduction of about 70–80% stri-
atal dopamine mainly leads to clinical diagnosis due to
the occurrence of the main motor symptoms and their
dopaminergic response. These motor features are akin-
esia, tremor and rigidity, sometimes even initially in
combination of postural disturbances, which mostly ap-
pear later in the course of the disease and do not re-
spond to dopaminergic stimulation. Therapeutic
approaches of non motor features gain increasing im-
portance in addition to motor symptoms control to im-
prove quality of life in PD patients and their caregivers
[1]. Long term treatment of this array of symptoms with
various drugs causes the occurrence of short - and long
term side effects. Course of PD, expression of motor andCorrespondence: th.mueller@alexius.de
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reproduction in any medium, provided the ornon motor symptoms, efficacy and tolerability of thera-
peutic interventions vary from one patient to another.
Therefore an individualized therapeutic regime is per-
formed with repeated control and titration by the treat-
ing physician in close cooperation with the patient and
his caregiver in clinical practice.Treatment of motor symptoms
Mainly akinesia, rigidity and clinical associated features
and to a lesser extent tremor respond to dopaminergic
stimulation in PD patients. Table 1 provides a proposal for
a treatment cascade of dopamine system influencing
compounds for PD patients with probable long necessary
dopamine substitution therapy following diagnosis.Monoaminooxidase B (MAO-B) inhibition
MAO-B-I stabilize the dopamine levels in the synaptic
cleft. Two compounds of the propargylamine group,
selegiline and rasagiline, both irreversible MAO-B inhi-
bitors, have demonstrated a symptomatic effect in PD
patients. MAO-B-inhibition catalyses the oxidative de-
amination of active amines and therefore causes pro-
longed dopamine activity. Selegiline and rasagiline areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Treatment cascade of current dopaminergic substitution tools with respect to the concept of continuous
dopaminergic stimulation
Drug Step Mode of action within
the dopaminergic
system
Tolerability Main clinical relevant side effects Efficacy
MAO-B-I I stabilize dopamine levels in the striatal
synaptic cleft by inhibition of dopamine
metabolism
+++ risk for rise of raised blood pressure and increase of liver
enzymes, contraindication for simultaneous fluoxetine and
fluvoxamine use, precaution with application of SSRI in general
+
NMDA-A I indirect dopaminergic modulation, reduce
motor complications (?)
+ oedema, insomnia, hallucinations +
DA II stimulate directly postsynaptic striatal
receptors linked to motor symptom
control
+ Orthostatic syndrome, oedema, nausea, slow titriation necessary ++
LD/DDI/COMT-I III precursor of dopamine, DDI and COMT-I
reduce LD metabolism
+++ orthostatic syndrome, homocysteine elevation (LD/DDI alone),





IV See DA, respectively LD line + Subcutaneous local inflammatory reactions +++
DBS V electric stimulation of the subthalamic
nuclei or globus pallidus
+ Social adjustment problems, depression, cognitive dysfunction. +++
DBS = deep brain stimulation, MAO-B-I = MAO-B-Inhibitors, NMDA-A = NMDA-antagonist, DA = dopamine agonist, LD = levodopa, DDI = decarboxylase inhibitor,
COMT-I = inhibitor of catechol-O-methyltransferase, judgement on tolerability and efficacy are based on the personal experience of the author.
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this selectivity gets lost at higher drug doses, i.e. selegi-
line> 20 mg/day and rasagiline> 2 mg/day. These
dosages also inhibit MAO-A, which converts other amines,
like norepinephrine. Therefore, although low, there is a risk
of tyramine-induced hypertension, which is called the
"cheese effect", at higher doses by these agents. These com-
pounds are also known to enhance the activity of catechola-
minergic neurons by mechanisms other than MAO-B
inhibition [2]. Other pharmacological activities such as ef-
fect on mitochondrial membrane potential activity, anti-
apoptotic and antioxidant efficacy may explain potential
neuroprotective mechanisms seen in the laboratory. Cor-
respondingly, clinical trials investigated this putative benign
influence on the course of PD [2].
MAO-B-I and progression of PD
The DATATOP study was a prospective, randomised,
double-blind, placebo-controlled study that included 800
patients with PD. After randomisation to either selegi-
line, α-tocopherol (vitamin E), a combination of both or
placebo, the patients were followed up with no other
treatment until clinical deterioration calling for initiation
of symptomatic therapy with Levodopa (LD) plus dopa-
decarboxylase inhibitor (DDI) as clinical endpoint. Sele-
giline, but not α-tocopherol, resulted in a significant
delay for LD/DDI requirement compared with placebo
(26 versus 15 months; p< 0.0001). However, this benefi-
cial effect of selegiline vanished in the further follow-up
investigations of the trial. The main limitation of this
study was the potential confounding symptomatic effect
of selegiline on the results. Further trials examined the
disease modifying potential of rasagiline. Both double-blind, parallel group, randomised, delayed-start clinical
studies, the TEMPO and the ADAGIO trial, included
early PD patients. They were randomised to receive rasa-
giline 1 or 2 mg/day or placebo for a certain period, fol-
lowed by rasagiline application in general. The relative
weak degree of motor improvement was comparable to that
seen for selegiline in the DATATOP study [3]. Patients who
received 1 mg rasagiline during the whole study interval
had less functional decline, as assessed by the Unified Par-
kinson’s Disease Rating Scale (UPDRS), than patients who
received placebo initially for a certain period [4,5]. All these
results support a certain disease modifying or progression
slowing effect of MAO-B-I, but curative therapeutic
approaches for PD are still elusive.
Dopamine agonists (DA)
Ergoline and non ergoline DA act directly on postsynap-
tic dopamine receptors without the need for metabolic
conversion to dopamine, storage and release in degener-
ating nigrostriatal nerve terminals. In addition, DA de-
crease endogenous dopamine turnover. All DA show a
limited tolerability due to predominant nausea and dizzi-
ness in the initiation period. Therefore DA titration is
performed in a slow and cautious manner. Additional
temporary intake of the world wide only partially avail-
able dopamine antagonist domperidone against nausea
and midodrine due to the onset of an orthostatic syn-
drome limit these side effects. Loss of appetite, sleepiness
and/or oedema may also occur and reduce compliance of
DA intake. The availability of various DA enables the
switch from one DA to another to test the individual
optimum tolerability and response (Table 2). Transder-
mal DA delivery with the rotigotine patch is also
Table 2 Current available, approved dopamine agonists
compound dose range administration half life
bromocriptine 10 - 50 oral, t.i.d. 3 – 6
lisurid 0.2 - 3 oral, 12 i.d. 2
pergolid 0.5 - 6 oral, t.i.d. 6-8
dihydro-α-ergocryptine 20 - 120 oral, t.i.d. 16
cabergoline 0.5 - 4 oral, o.i.d. 63
rotigotine 2 - 16 patch, t.i.d. 24
Pramipexol [retarded release] 0.25 - 4.5 oral, t.i.d.[o.i.d. – b.i.d.] 8 [24]
Ropinirol [retarded release] 4 - 24 oral, o.i.d. [o.i.d. – b.i.d.] 6 [24]
Piribedil retarded release 50 - 250 oral, t.i.d. 21
Dose range is given in mg, only approved dopamine agonist with oral or transdermal administration are listed, plasma half life is given in hours, 10 mg
bromocriptine correspond to approximately 400 mg LD/DDI.
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ately or after several months. This suggests a delayed aller-
gic immune reaction triggered with a still unknown long
lasting immune reaction cascade [6].
Why are non ergoline DA now preferred?
Ergoline DA induced fibrosis is the most serious and
sometimes life threatening condition with delayed ap-
pearance and diagnosis due to insidious onset and onset
of symptoms after several years of well tolerated DA
treatment. Possible mechanisms are an idiosyncratic im-
mune response with the drug acting as a hapten or an
altered function via long term 5-HT stimulation with a
consecutive induction of the key mediator of fibrosis,
the transforming growth factor-β 1 [7]. However, these
rarely occurring phenomena induced serious warnings
on long term ergoline DA intake i.e. pergolide, cabergo-
line [6].
The advantage of slow release DA tablets
Slow release non ergoline DA are available now. These for-
mulations showed a better tolerability and efficacy on
additional non motor symptoms, i.e. sleep, in clinical trials.
In daily practice, their handling is also better, since patients
are mostly asked to take the drug one time daily only,
which improves compliance (Table 2). Mixed results exist
in terms of efficacy of the slow release formulation in com-
parison with the conventional formulation. Ropinirole slow
release showed superior effect to normal released ropinirole
[8]. Pramipexole slow release only demonstrated non infer-
iority to normal release formulation [9].
NMDA-Antagonists
NMDA – antagonists, i.e. amantadine, improve motor
symptoms by an indirect dopamine stimulating effect,
particular infusions of amantadine sulphate are effica-
cious [10]. Clinical trials also showed a certain beneficial
effect on motor complications (MC), i.e. involuntary
movements or dyskinesia [11]. However there is need forfurther confirmatory placebo controlled trials [12]. Aman-
tadine may support onset of hallucinations, psychosis, in-
somnia and oedema [10,12].
Anticholinergics
Anticholinergics are nowadays rarely used due to per-
ipheral and central side effects, like mouth dryness, con-
stipation, miction problems, tachyarrhythmia, delirium
and dementia. Sometimes one may consider using anti-
cholinergic compounds for treatment of severe tremor
in younger PD patients without any cognitive distur-
bances [13].
Start of LD is a milestone
All the above mentioned compounds for dopamine
modulation or - substitution improve motor behaviour
in PD patients only to a certain extent. Therefore the
introduction of LD is a necessity at a certain moment,
which is looked upon as an essential milestone in each
life of a PD patient. LD is the most efficacious and best
tolerated compound for the control of motor symptoms
in PD patients.
Basic principles of LD administration
The introduction of LD was a pharmacological break-
through in the treatment of PD. Initially LD was given
as an infusion, then in oral form without inhibition of
LD degrading enzymes (Figure 1 A). Oral LD application
was later combined with DDI [14,15]. This pharmaco-
logical principle of enzymatic inhibition of LD metabol-
ism reduces the peripheral degradation of LD to
dopamine. Therefore, plasma half life of LD increases,
which results in a better efficacy of the compound (Fig-
ure 1B). DDI such as Benserazide (BE) and Carbidopa
(CD) do not cross the blood–brain barrier. Addition of
DDI to LD allows for a four- to fivefold oral LD dose re-
duction [16]. As a result, the frequency of LD-related
peripheral side effects, i.e. nausea and vomiting, lowers.

























Figure 1 Types of LD degradation without (1 A) and with (1 B,
1 C) inhibition of LD degrading enzymes.
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with the active large amino acid transporter of the
gastrointestinal tract and of the blood brain barrier
[17,18].
Supplementation of LD/DDI application with inhibitors of
catechol-O-methyltransferase (COMT)
Inhibition of LD degradation by combination with a DDI
supports LD metabolism via the enzyme COMT (Fig-
ure 1 B). As a result, an increased synthesis of the LD
metabolite 3-O-methyldopa (3-OMD) occurs. Blocking
of COMT activity further reduces peripheral LD degrad-
ation, as it prolongs plasma half life of LD and elevates
delivery of LD to the brain. Moreover the peripheral LD
degradation to 3-OMD is reduced. Experimental and
clinical outcomes confirmed the efficacy of this thera-
peutic principle with peripheral dual inhibition of both
main LD metabolizing enzymes (Figure 1 C) [16].Oral LD/DDI long term application and progression of PD
Following the introduction of oral LD/DDI treatment, a
debate was soon started on the saga of LD neurotoxicity.
This discussion based on the clinical observation of fluc-
tuations of movement as long term consequence of LD/
DDI treatment and on outcomes of experimental animal
– and cell culture studies [19]. As consequence, the Earl-
ier vs Later L-DOPA (ELLDOPA) trial was designed to
answer whether LD is harmful or not [20]. The ELL-
DOPA trial was the first double blind trial, which com-
pared the therapeutic efficacy of LD/CD in three
different daily dosages of 150 mg, 300 mg or 600 mg
with placebo treatment according to the guidelines of
good clinical practice in PD patients. Additionally func-
tional brain imaging with the [123 J]-β-CIT-SPECT was
employed as biomarker to evaluate the integrity of the
nigrostriatal system during LD treatment and to demon-
strate a PD accelerating effect of LD. The ELLDOPA
trial produced conflicting results. Treatment with LD/
DDI was associated with a significant increase in declin-
ing rates of [123J]-β-CIT imaging marker uptake over
nine months compared with placebo, a finding consist-
ent with a toxic effect of higher LD dosages. Clinical
evaluation, however, showed that patients on LD/DDI
treatment had better UPDRS scores compared with pla-
cebo administration after two weeks of washout. This
would, in contrast, be indicative of a protective, benign
PD modifying effect of LD. The simplest explanation for
this effect is that the washout period was too brief to
eliminate the symptomatic benefits of LD despite the
short plasma half life of the drug. An alternative perhaps
clinical more likely hypothesis may be that LD main-
tained body function and prevented onset of secondary
long term changes and adaptation occurring after the
manifestation of PD. This consideration may allow the
more general conclusion that the clinical results of the
ELLDOPA trial also support the concept of an early as
possible diagnosis of PD and a subsequent immediate
initiation of optimum treatment, as shown in the
TEMPO- and the ADAGIO-study [5,21].
Clinical efficacy of COMT-inhibition in combination with LD/
DDI
Numerous phase II, III and IV trials demonstrated that
COMT-inhibition with entacapone (EN) or tolcapone
given as extra tablet improves efficacy of LD/DDI [22]. A
further important trial on the efficacy of COMT inhib-
ition with EN was the FIRST-STEP (Favorability of Im-
mediate-Release Levodopa/Carbidopa vs STalevo Short-
Term comparison in Early Parkinson’s disease) study. It
aimed to compare the efficacy of these two different
modes of LD application, the conventional LD/CD ad-
ministration versus LD/CD with the COMT-inhibitor
EN in one tablet (LD/CD/EN) in early PD patients with
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randomized, parallel-group study administered a fixed oral
LD dose of 300 mg/day, distributed as 100 mg LD doses
three-times daily at 5-hour intervals to 424 PD patients. In
this 39 weeks lasting study, the PD patients in the LD/CD/
EN arm performed significant better than the ones in the
LD/CD treated cohort after week four throughout the
remaining course of the study. This was found when the
sum scores of the UPDRS part II (activities of daily living)
and UPDRS part III (motor examination) were compared
as main primary outcome at the remaining study visits. The
FIRST-STEP trial demonstrated that LD/CD was inferior to
LD/CD/EN treatment [23]. Thus it confirmed the known
additional LD/DDI efficacy enhancing effects of EN, when
given as extra tablet, to an existing LD/CD regimen in trea-
ted PD patients, which was proven by pharmacokinetic
investigations before [24].
Safety and tolerability of COMT-inhibitors
Phase III studies and post marketing surveillance showed
the safety, tolerability and efficacy of LD/DDI combination
with EN even with co-administration of selegiline, dopa-
mine agonists and antidepressants. The most common
observed side effect was harmless discoloration of the urine.
A further non dopaminergic adverse event of COMT inhib-
ition is diarrhoea sometimes occurring even up to two to
four months following treatment initiation. This may be
due to the inhibition of 5-HT metabolism in the gastro-
intestinal tract, which causes an increase of gastrointestinal
motility in some PD patients [25]. Centrally acting, stronger
direct EN competitor tolcapone was temporarily withdrawn
due to reports on serious hepatic reactions with develop-
ment of severe, sometimes even fatal, hepatic disease as
well as possible occurrence of rhabdomyolysis and neuro-
leptic malignant-like syndrome. Nowadays one assumes
that patients with mutations in the UDP-glucuronosyltrans-
ferase 1A9 gene, which leads to defective glucuronidation
activity, may predispose for tolcapone induced
hepatotoxicity.
Regulatory affairs
The discussion on the liver toxicity of tolcapone with a
demand for liver function tests on regular basis still bias
the preference for EN intake. An additional negative cri-
terion for tolcapone use is the need for a previous failed
response or intolerance of EN intake.
Oral intake of available COMT-Inhibitors
Tolcapone therapy asks for the additional intake of three
tablets to a consisting LD/DDI regime only. EN, given as an
extra tablet, should be combined with every LD/DDI intake
with an upper limit of a daily dose of 1600 mg EN. This
may increase the number of tablets and therefore may re-
duce the compliance. This disadvantage of EN therapy wasimproved with the introduction of the triple combination
LD/CD/EN, which allowed to reduce the number of tablet
intake and provided a smaller pill size. This further eased
swallowing and favoured patients’ acceptance [25].
Reasons for delayed LD treatment initiation in PD patients
Current guidelines suggest a delay of LD use in PD
patients as long as possible. Particularly, if one may as-
sume a further long lasting necessary treatment of PD
due to a relative young biological age. Avoidance of LD
implementation is known to postpone onset of MC. MC
limit quality of life and cause caregiver burden consider-
ably [26]. There is study based evidence that in the long
term outcome quality of life does not differ much de-
pending of which drug, levodopa or pramipexole, has
been used for treatment initiation. On the one hand LD
is associated with more MC. On the other hand prami-
pexole causes more acute side effects, i.e. nausea, and
less motor control [27].
Causes for the onset of MC
MC are fluctuations of movement behaviour dependent,
which is called predictable, respectively independent,
which is classified as unpredictable, on previous dopa-
minergic drug intake. MC are looked upon as a clinical
milestone, which indicates an advanced stage of PD. MC
are predominantly associated with oral LD/DDI treat-
ment, as LD has a short plasma half life. Accordingly
peaks and troughs of LD plasma levels appear. Following
the LD transport into the brain and the conversion to
dopamine in presynaptic neurons, fluctuations of dopa-
mine brain concentrations generate MC by irregular, not
continuous stimulation of nigrostriatal postsynaptic
dopamine receptors. Loss of presynaptic dopaminergic
autoreceptor function and other compensating abilities
to avoid not physiologic high dopamine concentrations
in the synaptic cleft are currently looked upon as the
main central cause for MC appearance. Onset of MC is
predominantly looked upon as the clinical consequence
of the induction of frequent alternating postsynaptic
dopamine receptor stimulation with further downstream
intracellular changes in neuronal nigrostriatal cells,
which regulate motor behaviour [26]. Continuous stimu-
lation of these postsynaptic dopamine uptake sites may
delay onset of MC, which often appear in combination
with a wide array of non motor symptoms [28]. However
peripheral components of drug intake, like compliance,
which is a problem in many PD patients, or absorption
of the applied compound often in combination with
other drugs may also influence the occurrence of MC.
Consequences of MC in clinical practice
Generally, intervals and intensity of MC may differ from
day to day. They may be brief or long, lasting between
Table 4 Rate of MC in the FIRST-STEP trial (%)
LD/CD/EN LD/CD Total
dyskinesia 2.7 4.2 3.5 week 39
wearing off 8.8 12.0 10.4 week 39
dyskinesia 5.3 7.4 6.4 at any study visit
wearing off 13.9 20 17 at any study visit
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ment behavior cause patient disability, embarrassment,
frustration [28]. The ELLDOPA trial confirmed the gen-
eral view, that the higher the daily administered LD dose
was, the more frequent MC were observed (Table 3).
Their occurrence rate was equal to placebo in the
150 mg daily LD dose treated cohort, but rose up to 3-
fold in the 600 mg daily dose treated group [21]. There-
fore generally, fear of MC limits the long term value and
the patients’ acceptance of LD/DDI intake.
MC: Wearing off
PD patients tend to experience fluctuations of move-
ment with progression of the disease. They switch from
ON to OFF and vice versa. The ON state is characterised
by good movement behaviour. OFF is associated with
temporary onset of the cardinal motor symptoms. When
this reappearance of motor symptoms indicates the de-
creasing efficacy of the last dopaminergic drug intake
before the next one, they are described as wearing-off.
EN and the treatment of wearing off
Both studies, FIRST-STEP and ELLDOPA, provided also
some interesting findings regarding the onset and fre-
quency of wearing off in PD patients (Tables 3 & 4). In
the FIRST-STEP trial, the number of monitored wearing
off was higher in the LD/CD - compared with the LD/
CD/EN treated PD patients (Table 3). The frequency of
noted wearing off phenomena was rather low in relation
to the size of the study population and the short obser-
vation interval. Therefore this did not turn out as statis-
tical relevant in the investigated early PD patients, who
were probably in the honeymoon period of LD applica-
tion with good tolerability and efficacy. This may indi-
cate that EN prevents onset of wearing off [23]. In the
ELLDOPA trial, the number of observed wearing off
increased with higher LD/CD dosing (Table 3). There-
fore one may assume that EN in combination with LD/
CD not only improves but also may prevent onset of
wearing off phenomena. Accordingly, pharmacokinetic
studies showed that EN supplementation to LD/CD
avoids troughs, elevates half life of LD and thus contri-
butes to more stable plasma levels after twice adminis-
tration every three hours. The prolongation of plasmatic
LD half life was even shown after one time application. All
these outcomes contribute to prevent and to improve wear-
ing off phenomena. The latter feature was the reason forTable 3 Frequency of MC in the ELL-DOPA trial (%)
LD/CD LD/CD LD/CD
150 mg 300 mg 600 mg Placebo
dyskinesia 3.3 2.3 16.5 3.3
wearing off 16.3 18.2 29.7 13.3approval of EN, but the value of EN supplementation to
LD/CD in the treatment or prevention of other kinds of
MC such as dyskinesia still remained unsolved.MC: Dyskinesia
Unwanted, abnormal involuntary movements are termed
as dyskinesia. They develop as a complication of dopa-
minergic stimulation. Dyskinesia can occur during both
ON and OFF intervals. Classification of dyskinesia is
generally performed in relation to the timing of LD dos-
ing. ON dyskinesia appears either during the period
when patients are obtaining maximal relief from their
motor symptoms. Then they are looked as peak-dose
dyskinesia. The maximum plasma LD level following in-
take may cause peak-dose dyskinesia as the most com-
mon form of these kind of involuntary movement
behaviour. They may be also biphasic, occurring soon
after LD is taken and as the patient is beginning to turn
ON and again when the LD effect is wearing off and the
patient is beginning to turn OFF. They are mostly absent
when the LD dose is having its maximal effect. As the
disease progresses, patients may develop dyskinesia
throughout the whole ON time. The risk of developing
dyskinesia has been associated with a number of clinical
factors. The severity of PD, the dosage and duration of
LD therapy, low body weight and a younger age of the
PD patient are currently believed to be among the vari-
ables that best predict the development of dyskinesia
[26].Continuous introduodenal LD/DDI treatment
Initially LD is well tolerated and provides no MC. This
is called the honeymoon period of LD therapy, followed
by the insidious onset of MC and associated non motor
features, when the drug efficacy vanes. Therefore
pharmacologic strategies were necessary to prolong the
half life of LD, as a more continuous LD delivery to the
brain helps to prevent and improve predominantly LD/
DDI associated MC [29]. The efficacy of this concept and
the importance of not fluctuating LD brain delivery were
convincingly shown by duodenal LD infusion systems, as
PD patients suffering from severe MC experienced an
enormous deterioration of the intensity and frequency of
MC due to the stable LD plasma concentrations. But
performance of duodenal LD infusions is a rather
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able demand for caregiver burden [30].
Preventive treatment concepts for dyskinesia
Studies in drug-naive animal models of PD have shown
that continuous dopaminergic stimulation is associated
with reduced incidence and severity of dyskinesia com-
pared with pulsatile administration. Continuous dopa-
minergic stimulation due to a more continuous delivery
of dopaminergic drugs to the brain may be achieved
through the administration of transdermal dopamine
agonist administration, retarded release dopamine ago-
nists or intra-duodenal LD application or to a lesser ex-
tent by administering frequent doses of LD/DDI, so
called LD fractionation, with or without a COMT
inhibitor.
COMT inhibition and dyskinesia onset
Addition of COMT-inhibitors to a LD/DDI regimen with-
out concomitant individual adaption of LD/DDI intake by
extension of dosing intervals or reduction of LD/DDI dos-
age may induce dyskinesia. Pharmacokinetic and clinical
trials on the effects of repeat COMT intake showed, that
the addition of COMT-inhibitors increases peak levels
and thus the amount of plasma LD, which is delivered to
the brain. Both may support onset of dyskinesia. Therefore
it is often necessary in clinical practice, to modify oral LD/
DDI intake, when a COMT inhibitor is additionally intro-
duced even in PD patients with wearing off. More gener-
ally these pharmacokinetic findings in PD patients and
healthy volunteers also suggest, that LD/CD/EN as first
line LD formulation may be more appropriate, as LD/CD/
EN provides less fluctuating LD plasma levels, as shown
by pharmacokinetic trials. Moreover from the clinical
point of view, LD therapy is less complex, when LD/CD/
EN is introduced as first line LD formulation, if tolerated,
in PD patients. This approach circumvents the above
mentioned COMT inhibitor related complex adaption of
LD intake following the onset of wearing-off phenomena.
The ELLDOPA study confirmed that LD dose is a factor
in causing dyskinesia and that these can even develop as
early as 5–6 months after treatment initiation. Patients re-
ceiving 600 mg/day experienced significantly more dyskin-
esia than patients receiving placebo, 150 or 300 mg/day
(p< 0.001). The FIRST-STEP trial reported a not sig-
nificant tendency towards a lower number of
observed dyskinesia in the LD/CD/EN treated arm
compared with the LD/CD treated PD patients
(Table 4) [23]. The study was not powered to demon-
strate this effect. An experimental animal trial showed
lower frequency and less intensity of dyskinesia, when
a treatment with LD/DDI with the COMT inhibitor
EN, given four times daily, was started right from the
beginning [31]. A further confirmatory result should beprovided by the outcomes of the STRIDE-PD study (STa-
levo Reduction In Dyskinesia Evaluation), however this trial
failed [32]. Nowadays it is known that repeat EN dosing
may increase of Cmax values of LD in plasma, which in turn
augments the risk for onset of dyskinesia. These pharmaco-
kinetic characteristics of LD plasma behaviour in the con-
text with EN supplementation to a LD/CD regimen was
underestimated respectively not known, when STRIDE-PD
was designed. However the design of STRIDE-PD did not
allow prolonging of dosing intervals or dose reduction after
initial EN supplementation to an existing LD/CD regimen
[22,33].
Failed earlier preventive strategies for MC onset by oral LD
application
Earlier, LD/DDI application with oral slow release for-
mulations were developed and tested as an alternative to
provide more constant LD plasma behaviour. Clinical
studies showed a reduced efficacy of these retarded re-
lease LD/CD formulations in comparison with conven-
tional LD/CD tablets, when the same oral LD dosage
was administered. Moreover they did not delay onset of
MC. However one must consider that these trials did
not evaluate MC with too much detail [34,35].
Current effective therapy regimen for alleviation of MC:
Deep brain stimulation and infusion techniques
Deep brain stimulation
Both sided deep brain stimulation (DBS) of the subthala-
mic nuclei reduces the dosages of dopaminergic drugs,
improves motor symptoms and motor complications,
but not speech, gait or postural dysfunction. This
method may cause social adjustment problems, depres-
sion and cognitive disturbances. Depression might occur
in the postoperative phase but there is no clear evidence
for DBS induced depression in the long term. When
respecting the inclusion criteria for DBS only distinct
cognitive functions like decline in word fluency can be
related to the DBS itself whereas general cognitive de-
terioration may rather be related to disease progression
itself [36-40]. Nevertheless careful selection of PD
patients without psychiatric and cognitive symptoms is
essential.
Infusion techniques
The present infusion systems administer dopaminergic
drugs continuously. They provide benefit on MC. Their
complex application and titration modes need to be sim-
plified. Local inflammatory subcutaneous noodles at the
subcutaneous DA administration site may appear. Apo-
morphine is mostly administered in combination with
other oral antiparkinsonian drugs. The duodenal LD/CD
pump system still suffers from hardware problems, i.e. at
the duodenal administration site. LD/CD is given in high
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neuropathy occurs, which is often associated with vita-
mine B deficiency [41,42]. Both systems are expensive
[30,43].
Dopamine substitution and non motor symptoms
Dopaminergic drugs improve the mainly dopamine
related motor symptoms in PD. They only partially influ-
ence non motor symptoms [1,44]. The drug therapy of
non motor features is complex due to possible occur-
rence of drug interactions, interference with side effects
and induction of altered pharmacokinetic behaviour of
dopamine substituting compounds. But drug treatment
of non motor symptoms in PD gains more and more
interest. Thus trials showed a moderate positive effect of
the dopamine agonist pramipexole on depression in PD
[45]. These investigations reflect a changing attitude
from the focus on the effects of centrally acting com-
pounds on the dopaminergic neurotransmission towards
a more general view of PD with consideration of neuro-
psychiatric features under long-term aspects. However,
PD drugs themselves may also contribute to onset of
non motor symptoms, such as visual hallucinations. This
complicates the differentiation from the disease process
itself.
Therapy of non motor features
Treatment of non motor symptoms in PD is important.
Course of PD, expression of motor - and non motor
symptoms, efficacy and tolerability of therapeutic inter-
ventions vary from one patient to another in clinical
practice. This asks for an individualized drug regime
with repeated control and titration by the treating phys-
ician in close cooperation with the patient and his care-
giver [44].
Sleep disturbances
Up to 75% of PD patients complain of insomnia particu-
larly during long-lasting sleep at night. Reduced mobility
related to akinesia may cause lowered turning move-
ments during bedtime. Onset of dystonic cramps or pain
due to increased stiffness may disturb sleep. Bladder dys-
function in combination with polyuria may cause further
sleep complications [44].
Therapy
Sleep-onset- as well as sleep maintenance insomnia is
often induced by dopamine deficiency during night time.
As consequence symptoms like nocturnal akinesia, noc-
turia and even periodic limb movements may occur. Re-
lief may be provided by intake of slow release LD/CD
(BE) preparations, their equivalent LD/CD/EN formula-
tions late in the evening and intake of slow release dopa-
mine agonists, respectively the rotigotine patch [46]. Afurther approach for more advanced PD patients may be
to take fast release or conventional LD/DDI formula-
tions during waking periods during the night. Since a
further frequent psychopathological feature of PD, de-
pression, may cause sleep disturbances, intake of seda-
tive antidepressant compounds is often recommended.
Retarded Melatonin and gabaergic drugs are also useful.
Zolpidem with its short half life or Zopiclon with a
longer half life are efficient drugs dependent on the kind
of sleep disturbance. Benzodiazepines especially in the
elderly may sometimes cause paradoxical reactions, such
as agitation. Moreover they may induce dependence.
Therefore they should be used cautiously. Sedative atyp-
ical antipsychotic agents, like clozapine or quetiapine,
should be given in the case of vivid dreams, in pre-
psychotic states and psychosis [44,47]. Sleep fragmenta-
tion, avoiding of alcohol, caffeine, nicotine etc. are essen-
tial not for additional drug intake demanding, initial
essential treatment options.
Sleepiness
Dopamine substitution itself may cause sleepiness and
fatigue sometimes combined with sudden so-called
“sleep attacks”during the day. PD patients complain of
these sedative adverse events following the direct admin-
istration of dopamine substituting drugs [44].
Therapy of daytime sleepiness
Methylphenydate, dextroamphetamine, pemoline, moda-
finil and amantadine are known to improve wakefulness
and vigilance. Therefore these compounds may provide
also a certain benefit on daytime sleepiness and sleep
attacks [48].
Depression
Apathy, anxiety, panic attacks as features of depression
appear not only in early stages but also in the further
course of PD frequently. A bad motor situation or motor
complications induce physical impairment and therefore
contribute to onset of depressive mood, as quality of life
is lowered. These reactive components in turn facilitate
onset of endogenous components of mood disturbances,
which are associated with the progressing chronic neu-
rodegeneration in non dopaminergic neurotransmitter
systems [44].
Therapy of depression
Concomitant psychotherapeutic and behavioural inter-
ventions are essential. Choice of the antidepressant drug
should consider its efficacy on the depression itself, its
long-term effect on the motor system, its potential for
interactions with the concomitant PD drugs, its specific
and non-specific drug side effects with regard to other
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ition, salivation, orthostasis.
Motor complications may also trigger anxiety and
panic attacks in predisposed PD personalities. Up to 64%
of PD patients additionally suffer from mood disorders,
which also impact their spouses with up to 34%. Effect-
ive antidepressant compounds are sedative (i.e. mirtaza-
pin) or more activating (i.e. citalopram) antidepressants
or compounds like bupropion, which influence noradre-
nergic or dopaminergic pathways, or nefazodone, trazo-
done and venlafaxine, which impact neurotransmission
of serotonin and norepinephrine. This impact on nor-
epinephrine turnover is under suspicion to improve
orthostatic syndrome, however convincing trials are not
available. Tricyclics should be avoided in particular due
to their anticholinergic properties, as they may facilitate
onset of cognitive disturbances in the long term in the
elderly PD patients [44]. One small study even reports
more responders, when tricyclics are employed for ther-
apy of depression in PD [49]. Another trial however
emphasizes the lower tolerability of desimipramine in
comparison with citalopram and placebo [50].
Cognition in PD patients
Cognitive slowing and apathy may respond to optimum
dopamine substitution, as they are triggered by parts of
the dopamine innervated mesolimbic system. The bor-
ders towards a disturbed memory function are fluent.
Clinical initial symptoms of dementia are deficits of at-
tention, cognitive slowing, executive, visual spatial and
memory dysfunction, an increased vulnerability for onset
of illusions or optic hallucinations by centrally acting
drugs. However a clear distinction between apathy, de-
pression and dementia based on clinical observation
only is difficult. A distinct cholinergic deficit in PD
patients is looked upon as the main cause from the
neurochemical point of view [51].
Drug therapy of cognitive problems
Inhibitors of acetylcholinesterase improve symptoms of
dementia in PD patients and allied conditions. Predom-
inant open label smaller trials with donepezil and rivas-
tigmine demonstrated a better cognitive function in
various kinds of patients with impairment of motor and
cognitive function, whereas memantine only showed a
limited effect. Rivastigmine, an inhibitor of both acetyl-
cholinesterase and butyrylcholinesterase, produced a
moderate but significant improvement in global ratings
of dementia, cognition with measurements of executive
functions and attention, and neuropsychiatric behav-
ioural symptoms among patients with dementia asso-
ciated with PD [52]. This effect is in particular
pronounced in PD patients with a homocysteine eleva-
tion [53]. This effect of elevated homocysteine levelassociated therapy response was also seen with meman-
tine [54].
Psychosis
The chronic neurodegenerative process and the con-
comitant chronic dopaminergic stimulation predispose
for onset of psychosis probably triggered by an imbal-
ance between the dopaminergic and glutamatergic sys-
tem. Vivid dreams, fear, predominant optic illusions,
anxiety, paranoia, hallucinations and loss of sleep are ini-
tial clinical signs similar to delirium [44]. Occurrence of
symptoms may be predisposed by the premorbid person-
ality structure.
Symptomatic causes of psychosis
Generally, nearly each PD drug may cause psychosis in
particular in combination with dehydration. First hydra-
tion and then careful reduction of dopaminergic drugs
with subsequent reduced motor function are the most
useful clinical means to treat and avoid exacerbation of
psychosis. Treatment of additional concomitant infec-
tions or other general diseases, which may induce psych-
osis and/or delirium, is often necessary. Reduction of
medical, social or other kinds of stress, i.e. surgery,
change of environment, are further useful means.
Drug treatment of psychosis
Since classical neuroleptics, like butyrophenones or phe-
nothiazines, increase extrapyramidal symptoms, prepon-
derantly atypical neuroleptics are used for prevention
and treatment of psychotic symptoms in PD. The atyp-
ical antipsychotic agent clozapine is well tested in clin-
ical trials, shows additional sedative and tremorlytic
components and prevents recurrence of psychosis. How-
ever rare induction of leucopenia with resulting neces-
sary blood counts on a regular basis and sometimes
initially occurring transient subfebrile temperatures lim-
its its use. Since clozapine is metabolized via CYP1A2,
CYP3A4, CYP2C19 and CYP2D6, increase of drug levels
and/or intoxications may appear in combination with
drugs, which have these metabolic pathways, i.e. SSRIs,
like paroxetine or fluvoxamine, phenothiazines and
related compounds [44]. Quetiapine, which shares a cer-
tain structural similarity to clozapine, has the same anti-
psychotic efficacy. But the sedative components are not
so pronounced. This is a drawback in the case of acute
psychosis treatment. However this drug has a distinct
lower muscarinergic potency in comparison with cloza-
pine [55]. Quetiapine is also known, to enhance dopa-
mine enrichment in the prefrontal cortex, therefore it
may reduce cognitive slowing [56]. Accordingly, several
open trials even reported improvement of cognitive
function even in PD patients, who did not respond to
clozapine. This is an effect that may essentially reduce
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more suitable for the long-term use of antipsychotics for
treatment or even prevention of onset of psychosis,
which is often performed in clinical practice in order to
achieve a better motor condition in advanced PD
patients. However quetiapine failed in clinical trials in
these indications in PD patients. Therefore it is not
regarded as useful as clozapine by evidence based medi-
cine recommendations, whereas clinicians widely use
this compound sometimes even off label for the treat-
ment of their PD patients in some countries [57]. Fur-
ther treatment options are sedative and less cheaper
antipsychotic drugs with a low dopamine receptor block-
ing potential, like the buthyrophenones melperone or
pipamperone. However these compounds also worsen
the motor situation in the long run similar to other so-
called atypical high potential antipsychotic compounds,
like olanzapine and risperidone. Other antipsychotic typ-
ical drugs, like the butyrophenone haloperidol or the
thioxanthene flupentixol, should be avoided due to their
high affinity to postsynaptic dopamine receptors.
Cyclic mood disorder with hypomania or manic
psychosis
Manic episodes or psychosis are often associated with
dopamine dysregulation syndromes, more rarely they
appear following deep brain stimulation. Treatment options
are atypical neuroleptics, i.e. clozapine and/or quetiapine.
An alternative may be reduction of dopamine replacement
therapy however this will worsen the motor situation [58].
Dopamine related impulsive-compulsive disorders
Noticeable problems of the impulsive-compulsive spectrum
do not occur so frequently, but their onset may be related
to PD itself, to the pharmacological management of PD or
to both. These diseases comprise dopamine deficiency syn-
drome with immediate reward seeking behaviour, dopa-
mine dependency syndrome with addiction and dopamine
dysregulation syndrome with both addiction and stereo-
typed behaviour. Additionally impulse control disorders,
like pathological gambling, compulsive shopping, binge eat-
ing, punding and hypersexuality, are observed. These
changes are especially seen in PD patients with young age
of onset, higher dosing of dopamine substituting com-
pounds, depression, recreational drug or alcohol abuse, and
high novelty seeking personality traits. The role of dopa-
mine in the mesolimbic brain structures points out,
that this amine is not only involved in voluntary
movement control. Thus dopamine also plays an es-
sential role in the reward system and the modulation
of behaviour. Consequently most if not all drug-naive
PD patients suffer from dysphoria, leading to mild
immediate reward seeking behaviour. Some patients
under dopamine substitution demand for the intake ofincreasing quantities of LD, above those required to ad-
equately treat motor features of PD. Therefore they
show all characteristics of a dopamine dependency.
These patients may also develop plastic changes in the
striatal matrix, which may support onset of dyskinesia,
caused by extracellular fluctuations of striatal dopamine
levels due to pulsatility of dopamine replacement. As
soon as these changes are also seen in the striatal strio-
somes, in the framework of a dopamine dysregulation
syndrome, stereotyped behaviours, like punding, may
occur. Thus impulse control disorders may be regarded
as adverse side-effects of stimulation with dopamine
[59].
Treatment concepts
Treatment of impulse control disorders is associated to
the underlying pathophysiology. In the case of dopamine
deficiency, dopamine replacement will help. Psychosocial
strategies will help to improve the multifactorial dopamine
dependency and dysregulation syndromes, respectively ad-
dictive behaviour. Stereotyped behaviour, like punding,
may be covered by continuous dopaminergic receptor
stimulation. In case of i.e. drug induced or extrinsic im-
pulse control disorders, a therapy concept may be the re-
duction or the replacement of dopamine receptor agonists
[59]. In case of pathological gambling, this may be asso-
ciated with other abnormal actions such as pathological
shopping, hoarding and hypersexuality. The incidence of
these syndromes varies widely from study to study but
may be up to up to 13.6% of users of dopaminergic agents
[60]. Recognition of this problem has led drug regulatory
agencies to add precautions concerning pathological gam-
bling to official drug information for the entire class of PD
drugs. The literature is not entirely consistent and opi-
nions differ greatly, but the combined dopamine D2/D3
receptor agonists pramipexole and ropinirole may be es-
pecially likely to be associated with pathological gambling.
However the precise nature of the relationship is unclear
and may also be related to the widespread use of these
two compounds. It must be emphasized, that clear treat-
ment strategies are not available yet. However these syn-
dromes gain more and more attention.
Autonomic failures
Autonomic dysfunction may considerably reduce quality
of life, in particular in advanced PD stages [44]. Treat-
ment options of autonomic features seborrhea, hyperhi-
drosis, orthostatic syndrome, excessive salivation,
bladder dysfunction, gastrointestinal disturbances are
given in table 5.
Pain and sensory symptoms
Pain is often proportional to the degree of motor dys-
function and may take the form of muscle cramps,
Table 5 Treatment options of autonomic failures in Parkinson’s disease
symptom treatment options




constipation Various kinds of laxatives, sufficient hydration, fibers, prucaloprid (ReselorW), macrogel (MovicolW)
gastrointestinal
motility
Domperidone, prucaloprid (ReselorW) (off label use !)
bladder dysfunction genneral approach: reduced fluid intake at night is sometimes helpful. parasympatholytics, imipramine, Fesoterodinfumarat
(ToviazW) Darifenacin (Emselex W), botulinum toxin (off label use !) (in case of imperative urgency due to overactive bladder
syndrome [detrusor hyperreflexia or overactivity]) optimum dopaminergic drug titration (in case of frequent and/or involuntary
urinary incontinence due to uninhibited contractions of the detrusor muscle) distigmine bromide, reduction of anticholinergic
drugs, (in case of detrusor hyporeflexia [underactivity])
sexual dysfunction sildenalfil, oral apomorphine, alprostadil, psychotherapy
orthostatic
syndrome
patient education, non pharmacological interventions, midodrine, fludrocortisone, yohimbine, droxidopa
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complaints appear as numbness, burning or tingling and
occur at any stage of the disease. Sometimes they are inde-
pendent of medications and the degree of motor deficits,
but they may also appear in relation to motor fluctuations.
Treatment options are local botulinum toxin applications,
subcutaneous apomorphine injections, fast absorbed, sol-
uble LD preparations and symptomatic pain relief with
antirheumatic compounds or gabapentin, pregabalin in
the case of additional painful polyneuropathy [44].
Osteopenia and sceletal deformaties
Deformaties of feet and hands are common in PD. Coinci-
dent with rigidity, changes occur in the curvature of the
spine. Initially mild scoliosis may occur, concave contra lat-
eral to the affected side. Later kyphosis becomes prominent
and supports onset of postural instability. Osteopenia may
contribute to those deformities to a large extent. High
prevalence of hip and other fractures in PD is not only due
to increased number of falls because of problems of gait
and postural instability, but also because of reduced bone
mineral density due to a deficiency of 1,25-dihydroxyvita-
mine D, 25-hydroxyvitamine or an age related reduction of
the amount of 1 α-hydroxylase. Therapeutic options are
supplementation with calcium plus 1α-hydroxyvitamine D3
[44].
Cure: Still a dream
Neuroregenerative transplantation - and curative growth
factor trial outcomes disappointed. Future stem cell therapy
is far from clinical testing. The essential problem of all
these more regenerative therapeutic approaches is their
specific focus on the dopamine system without consider-
ation of altered non dopaminergic neurotransmitter bal-
ance in PD and the missing control of dopamine release to
the nigrostriatal system in a physiologic manner. Thereforethe transplantation trials in idiopathic PD patients failed.
Onset of dyskinesia and cognitive disturbances, which
hypothetically result from dopamine overflow after a cer-
tain interval, were observed in the clinic [61]. A further ap-
proach is gene delivery of the trophic factor neurturin via
an adeno-associated type-2 vector. Trials are ongoing [62].Conclusions
PD patients do not only suffer from motor symptoms, but
also from non motor features. Thus treating PD patients
asks for an individual and holistic approach. Therefore ther-
apy recommendations for PD patients only based on the
so-called evidence based medicine, which overemphasizes
the value of clinical randomized placebo controlled studies
according the guidelines of good clinical practice with its
selected patient populations, are somewhat “foolish” and
beyond reality in clinical practice [57]. Putative interactions
between various applied drugs, recurrent appearance of
non motor features and treatment of motor symptoms ask
for complex therapeutic interventions and careful drug ti-
tration. Reduction of dopaminergic drugs and hydration
may sometimes be more beneficial than addition of further
compounds. This also avoids compliance problems and
reduces individual differing tolerability of additional drugs
for non motor symptoms. Long-term experience for the
combined use of these supplementary drugs with dopamin-
ergic agents is essential to achieve an improvement of qua-
lity of life and to prevent onset of drug side effects.
Specialist knowledge of internal medicine, psychiatry and
pharmacology is advantageous in order to avoid drug inter-
actions with PD drugs and to guarantee adequate treat-
ment. The choice of these supplementary agents must be
considered very carefully and the start of additional applica-
tion must be performed slow and cautious. Therapeutic
options are often limited because of additional morbidity
and concomitant drug therapy.
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